CLASSIFICATION: RESEARCH PEPTIDE
ACTIVE SUBSTANCE: PE 22-28
FORM: LYOPHILIZED POWDER (2 ML VIAL x 10 MG)
ACTIVE HALF-LIFE: ~2-4 HOURS
DOSAGE: 500-2000 MCG PER DAY
ACNE: LOW RISK
WATER RETENTION: VERY LOW RISK
HIGH BLOOD PRESSURE (HBP): LOW RISK
HEPATOTOXICITY: NO REPORTED RISK
AROMATIZATION: NONE
MANUFACTURER: DRAGON PHARMA
Dragon Pharma presents its premium research compound, PE 22-28 10 mg, packaged as a high-purity lyophilized powder in a sterile 2 mL vial. Designed for scientific investigation into muscle physiology, this synthetic fragment of the pituitary adenylate cyclase-activating polypeptide (PACAP) has garnered significant interest in the research community for its potential anabolic and metabolic properties. As a trusted manufacturer, Dragon Pharma ensures stringent quality control, offering researchers a reliable and potent product for studying pathways related to hypertrophy, strength, and tissue repair. This guide provides a comprehensive overview for responsible research design involving PE 22-28.
PE 22-28 is a synthetic peptide fragment derived from PACAP (1-28). PACAP is a naturally occurring neuropeptide that plays a vital role in various physiological processes, including neurotransmission, metabolism, and cellular growth. The specific 22-28 sequence has been isolated for research due to its proposed binding affinity and activity. While full-length PACAP is involved in broad systemic functions, the PE 22-28 fragment is of particular interest for studies focused on skeletal muscle. Research, such as that cited in scientific literature on PubChem, explores how certain peptide sequences can influence cellular signaling. It is crucial to note that all applications discussed are strictly for non-human, in-vitro research purposes.
In experimental models, PE 22-28 is observed to influence pathways that could be relevant to muscle anabolism and performance. Its proposed mechanism involves interaction with specific receptor sites, potentially modulating signals that affect protein synthesis, glucose metabolism, and cellular energy utilization. Researchers have noted its potential role in promoting a more anabolic environment within muscle tissue, which may support investigations into hypertrophy (muscle growth) and the inhibition of catabolic (muscle-wasting) processes. Furthermore, its impact on metabolic rate and nutrient partitioning makes it a compound of interest for studies on body composition. Unlike traditional anabolic agents, PE 22-28 operates through a unique peptide pathway, offering a different research angle for understanding muscle adaptation and recovery from stress or exertion.
For research purposes, PE 22-28 is typically reconstituted with bacteriostatic water. The standard research dosage in preclinical models often ranges from 500 mcg to 2000 mcg per day, often divided into multiple administrations due to its relatively short half-life. The 10 mg vial from Dragon Pharma allows for flexible dosing protocols. A common research approach involves starting at the lower end of the range (e.g., 500-1000 mcg daily) to observe the model's response before any adjustment. Administration is typically via subcutaneous injection in animal models. The precise dosage and protocol must be determined by the research objectives and the specific model system in use. Consistency in timing and administration route is critical for generating reliable data.
Research cycles with PE 22-28 are generally shorter than with traditional, long-ester compounds, often lasting 4 to 8 weeks in experimental designs. Due to its fast-acting nature, effects may be observed more rapidly in research settings. To study synergistic effects or support specific research goals, PE 22-28 is often combined with other compounds in a "stack." Here are several Dragon Pharma products that researchers may consider for complex study designs on muscle growth, fat loss, and recovery:
These stacks should only be designed within the context of controlled, ethical laboratory research.
In animal research models, PE 22-28 is generally well-tolerated at standard research doses. However, as with any bioactive compound, potential adverse effects are monitored. These may include transient issues at the injection site (redness, itching), mild fluctuations in blood glucose levels, or increased appetite in some models. Due to its mechanism, there is no risk of estrogenic, androgenic, or progestagenic side effects such as gynecomastia, hair loss, or virilization. It is not hepatotoxic. Responsible research mandates regular monitoring of the subject's physiological parameters. Any research involving peptides must adhere to strict sterile techniques to prevent infections.
PE 22-28 has a relatively short half-life, estimated to be between 2 to 4 hours in circulation. This necessitates frequent administration in research protocols to maintain stable plasma levels. Its short half-life and peptide nature also mean it has a very short detection window. It is rapidly broken down into its constituent amino acids, making it undetectable via standard steroid screening methods shortly after administration ceases. This pharmacokinetic profile is a key consideration for research timeline planning.
Selecting Dragon Pharma ensures the highest standard of quality and purity for your research. Our PE 22-28 10 mg undergoes rigorous third-party testing to verify peptide content, sterility, and the absence of endotoxins or contaminants. We provide secure, discrete shipping within the USA, ensuring your research materials arrive promptly and in optimal condition. By choosing a reputable source like Dragon Pharma, researchers can have confidence in the consistency and reliability of their compounds, which is foundational for generating valid and reproducible scientific data.
In scientific research, PE 22-28 is primarily studied for its potential effects on skeletal muscle tissue. The focus areas include its role in modulating protein synthesis pathways (potentially supporting hypertrophy), influencing metabolic rate and nutrient partitioning, and impacting recovery processes. It provides a unique research model for studying peptide-mediated anabolism outside of classical steroid receptor pathways.
Reconstitute the lyophilized powder with an appropriate volume of bacteriostatic water. For example, adding 2 mL of bacteriostatic water to the 10 mg vial will yield a concentration of 5 mg/mL (or 5000 mcg/mL). Use sterile techniques, gently swirl (do not shake vigorously) until the solution is clear. Store the reconstituted peptide in a refrigerator and use it within a few days for optimal stability.
Yes, researchers often design complex studies using stacks. PE 22-28 may be combined with other non-peptide anabolics like Methyl-1-Test 10 for strength, metabolic modulators like GW501516 for fat loss studies, or healing peptides like BPC 157. Stacks with compounds like DSIP can be used to study recovery. Always design stacks based on specific, hypothesis-driven research goals.
While both are peptides, their mechanisms differ. GHRP-6 primarily works by stimulating ghrelin receptors to potently increase Growth Hormone (GH) and IGF-1 release. PE 22-28 is a fragment of PACAP and is researched for its more direct potential effects on muscle tissue and metabolism, not primarily through the GH/IGF-1 axis. Their research applications, side effect profiles, and dosing patterns are therefore distinct.
No. PE 22-28 does not suppress the hypothalamic-pituitary-testicular axis (HPTA) like androgenic anabolic steroids. It operates through a different pathway and does not significantly alter endogenous testosterone production in research models. Therefore, a traditional SERM-based PCT (e.g., with Clomid or Nolvadex) is not indicated or necessary following a research cycle of PE 22-28 alone.
Please log in to write PE 22-28 10 MG review.
CLASSIFICATION: RECOMBINANT HUMAN GROWTH HORMONE (rHGH)
ACTIVE SUBSTANCE: SOMATROPIN
FORM: 1 PRE-FILLED PEN x 36 IU (12 MG)
ACTIVE HALF-LIFE: ~3.5 HOURS (SUBQ)
DOSAGE: 1–4 IU/DAY FOR ANTI-AGING; 4–8 IU/DAY FOR FAT LOSS OR PERFORMANCE
WATER RETENTION: POSSIBLE (DOSE DEPENDENT)
HEPATOTOXICITY: NONE
AROMATIZATION: NO
MANUFACTURER: PFIZER
CLASSIFICATION: RECOMBINANT HUMAN GROWTH HORMONE (r-hGH)
ACTIVE SUBSTANCE: SOMATROPIN (R-HGH)
FORM: 1 CARTRIDGE x 15 MG
ACTIVE HALF-LIFE: ~2–3 HOURS
DOSAGE: MEN 4-10 IU/DAY
ACNE: POSSIBLE
WATER RETENTION: POSSIBLE
HIGH BLOOD PRESSURE (HBP): MAY INCREASE VIA FLUID RETENTION
HEPATOTOXICITY: NONE TYPICAL
AROMATIZATION: NONE
MANUFACTURER: NOVO NORDISK
CLASSIFICATION: GONADOTROPIN (LH RECEPTOR AGONIST)
ACTIVE SUBSTANCE: HUMAN CHORIONIC GONADOTROPIN
FORM: 1 LYOPHILIZED VIAL x 5000 IU + PROVIDED SOLVENT
ACTIVE HALF-LIFE: ~24–36 HOURS
DOSAGE: MEN 500-1000 IU
ACNE: POSSIBLE
WATER RETENTION: POSSIBLE
HIGH BLOOD PRESSURE (HBP): MONITOR IF AT CV RISK
HEPATOTOXICITY: NONE TYPICAL
AROMATIZATION: INDIRECT
MANUFACTURER: IBSA
CLASSIFICATION: PEPTIDE HORMONE / HCG
ACTIVE SUBSTANCE: HUMAN CHORIONIC GONADOTROPIN
FORM: 1 ML AMP x 5000 IU
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3x/WEEK (ON-CYCLE or PCT)
ACNE: POSSIBLE
WATER RETENTION: MODERATE
HIGH BLOOD PRESSURE (HBP): UNLIKELY
HEPATOTOXICITY: NONE
AROMATIZATION: INDIRECTLY ELEVATES ESTROGEN
MANUFACTURER: SUN PHARMA
CLASSIFICATION: PEPTIDE HORMONE / HCG
ACTIVE SUBSTANCE: PRE-MIXED HUMAN CHORIONIC GONADOTROPIN
FORM: 1 VIAL x 10000 IU (READY-TO-INJECT)
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3x/WEEK (ON-CYCLE or PCT)
ACNE: POSSIBLE
WATER RETENTION: LOW to MODERATE
HIGH BLOOD PRESSURE (HBP): RARE
HEPATOTOXICITY: NONE
AROMATIZATION: INDIRECTLY INCREASES ESTROGEN
MANUFACTURER: BHARAT SERUMS AND VACCINES